These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 21225122

  • 81. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
    Sampaio C, Ferreira JJ, Simões F, Rosas MJ, Magalhães M, Correia AP, Bastos-Lima A, Martins R, Castro-Caldas A.
    Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
    [Abstract] [Full Text] [Related]

  • 82. Clinical features and response to botulinum toxin in primary and secondary hemifacial spasm.
    Pandey S, Jain S.
    Neurol India; 2018 Nov; 66(4):1036-1042. PubMed ID: 30038089
    [Abstract] [Full Text] [Related]

  • 83. Local injection of botulinum toxin type A for hemifacial spasm.
    Oyama H, Ikeda A, Inoue S, Nakashima Y, Shibuya M.
    Neurol Med Chir (Tokyo); 2002 Jun; 42(6):245-8; discussion 248-9. PubMed ID: 12116529
    [Abstract] [Full Text] [Related]

  • 84. Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections.
    Price J, Farish S, Taylor H, O'Day J.
    Ophthalmology; 1997 May; 104(5):865-8. PubMed ID: 9160036
    [Abstract] [Full Text] [Related]

  • 85. Botulinum a toxin treatment of hemifacial spasm and blepharospasm.
    Park YC, Lim JK, Lee DK, Yi SD.
    J Korean Med Sci; 1993 Oct; 8(5):334-40. PubMed ID: 8305141
    [Abstract] [Full Text] [Related]

  • 86. Effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial spasm compared to standard care: study protocol for a randomised controlled trial.
    Wickwar S, McBain H, Newman SP, Hirani SP, Hurt C, Dunlop N, Flood C, Ezra DG.
    Trials; 2016 Mar 09; 17(1):129. PubMed ID: 26961367
    [Abstract] [Full Text] [Related]

  • 87. Effect of dietary zinc and phytase supplementation on botulinum toxin treatments.
    Koshy JC, Sharabi SE, Feldman EM, Hollier LH, Patrinely JR, Soparkar CN.
    J Drugs Dermatol; 2012 Apr 09; 11(4):507-12. PubMed ID: 22453589
    [Abstract] [Full Text] [Related]

  • 88. [Changes in dose and injection pattern in the botulinum toxin long-term therapy of facial dyskinesis].
    Laskawi R, Niemczewska A, Schneider S, Winterhoff J, Beutner C, Rohrbach S.
    Laryngorhinootologie; 2014 Mar 09; 93(3):186-92. PubMed ID: 24323508
    [Abstract] [Full Text] [Related]

  • 89. Influence of involuntary eyelid spasms on corneal topographic and eyelid morphometric changes in patients with hemifacial spasm.
    Osaki T, Osaki MH, Osaki TH, Hirai FE, Nallasamy N, Campos M.
    Br J Ophthalmol; 2016 Jul 09; 100(7):963-970. PubMed ID: 26541432
    [Abstract] [Full Text] [Related]

  • 90. A comparative study of tear secretion in blepharospasm and hemifacial spasm patients treated with botulinum toxin.
    Price J, O'Day J.
    J Clin Neuroophthalmol; 1993 Mar 09; 13(1):67-71. PubMed ID: 8501266
    [Abstract] [Full Text] [Related]

  • 91. [Results of long term treatment of essential blepharospasm and facial hemispasm with botulinum toxin A].
    Ziak P.
    Cesk Slov Oftalmol; 2004 Jan 09; 60(1):37-44. PubMed ID: 15011305
    [Abstract] [Full Text] [Related]

  • 92. Facial muscle spasms: an Australian study.
    Kowal L, Davies R, Kiely PM.
    Aust N Z J Ophthalmol; 1998 May 09; 26(2):123-8. PubMed ID: 9630292
    [Abstract] [Full Text] [Related]

  • 93. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.
    Bhidayasiri R, Cardoso F, Truong DD.
    Eur J Neurol; 2006 Feb 09; 13 Suppl 1():21-9. PubMed ID: 16417594
    [Abstract] [Full Text] [Related]

  • 94. Injecting botulinum toxin into the treatment of blepharospasm.
    Popescu MN, Popescu SI, Cernat CC, Boariu AM, Călin E, Vieru A, Muşat O.
    Rom J Ophthalmol; 2018 Feb 09; 62(2):162-165. PubMed ID: 30206561
    [Abstract] [Full Text] [Related]

  • 95. [Focal dystonias and facial hemispasm: treatment with botulinum A toxin].
    Astarloa R, Morales B, Sánchez V, Peñafiel N, Rábano J, Oliván J, García de Yébenes J.
    Arch Neurobiol (Madr); 1991 Feb 09; 54(5):210-7. PubMed ID: 1804035
    [Abstract] [Full Text] [Related]

  • 96. [Focal dystonias and facial hemispasm: treatment with botulinum A toxin].
    Astarloa R, Morales B, Sánchez V, Peñafiel N, Rábano J, Oliván J, García de Yébenes J.
    Arch Neurobiol (Madr); 1991 Feb 09; 54 Suppl 3():44-51. PubMed ID: 1810208
    [Abstract] [Full Text] [Related]

  • 97. Which factors impact on quality of life for adults with blepharospasm and hemifacial spasm?
    Lawes-Wickwar S, McBain H, Hirani SP, Hurt CS, Dunlop N, Solly D, Crampton B, Newman SP, Ezra DG.
    Orbit; 2021 Apr 09; 40(2):110-119. PubMed ID: 32116098
    [Abstract] [Full Text] [Related]

  • 98. Demographic and clinical features of patients with blepharospasm in southern Taiwan: a university hospital-based study.
    Hwang WJ.
    Acta Neurol Taiwan; 2012 Sep 09; 21(3):108-14. PubMed ID: 23196730
    [Abstract] [Full Text] [Related]

  • 99. Botulinum neurotoxin in the treatment of hemifacial spasm associated with myasthenia gravis.
    Elavarasi A, Goyal V.
    Toxicon; 2021 Jan 30; 190():1-2. PubMed ID: 33253699
    [No Abstract] [Full Text] [Related]

  • 100. Botulinum neurotoxin for the treatment of movement disorders.
    Kopanidis P, Das C.
    Aust J Gen Pract; 2018 Sep 30; 47(9):598-601. PubMed ID: 30244558
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.